Folinic acid plus high-dose 5-fluorouracil with allopurinol protection in the treatment of advanced colorectal carcinoma

Eur J Cancer. 1990;26(10):1054-6. doi: 10.1016/0277-5379(90)90050-4.

Abstract

Protection by prolonged administration of allopurinol against high-dose 5-fluorouracil (5-FU) administered with folinic acid in 74 patients with colorectal cancer was investigated. The dose of 5-FU was 700 mg/m2 per day for 5 days. Of 41 patients without previous chemotherapy, 1 had a complete response and 4 had partial responses (total 12%), 15 remained stable and 21 progressed. Mean duration of response was 7.4 (1.8-12.6) months. The most frequent toxicities were decreased granulocytes (13%), diarrhoea (37%), and stomatitis (35%), which were similar to the frequencies of other studies with lower doses of 5-FU without allopurinol. Prolonged administration of allopurinol thus gives some protection to patients with colorectal cancer who receive folinic acid plus high-dose 5-FU but responses were not better than those with conventional doses.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Allopurinol / therapeutic use*
  • Colorectal Neoplasms / drug therapy*
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Female
  • Fluorouracil / administration & dosage
  • Fluorouracil / therapeutic use*
  • Fluorouracil / toxicity
  • Humans
  • Leucovorin / therapeutic use*
  • Male
  • Middle Aged

Substances

  • Allopurinol
  • Leucovorin
  • Fluorouracil